Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $112.89 in the prior trading day, Insmed Inc (NASDAQ: INSM) closed at $122.0, up 8.07%. In other words, the price has increased by $8.07 from its previous closing price. On the day, 7.25 million shares were traded. INSM stock price reached its highest trading level at $122.03 during the session, while it also had its lowest trading level at $112.48.
Ratios:
Our goal is to gain a better understanding of INSM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.33 and its Current Ratio is at 6.68. In the meantime, Its Debt-to-Equity ratio is 0.59 whereas as Long-Term Debt/Eq ratio is at 0.59.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on May 13, 2025, initiated with a Buy rating and assigned the stock a target price of $105.
On February 25, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $100.
On April 23, 2024, Truist started tracking the stock assigning a Buy rating and target price of $48.Truist initiated its Buy rating on April 23, 2024, with a $48 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 12 ’25 when SHAROKY MELVIN MD bought 10,000 shares for $121.53 per share.
Lewis William sold 6,830 shares of INSM for $750,008 on Aug 04 ’25. The Chair and CEO now owns 233,924 shares after completing the transaction at $109.81 per share. On Aug 04 ’25, another insider, Flammer Martina M.D., who serves as the Chief Medical Officer of the company, sold 8,715 shares for $109.50 each. As a result, the insider received 954,292 and left with 83,111 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INSM now has a Market Capitalization of 25787750400 and an Enterprise Value of 24670001152. For the stock, the TTM Price-to-Sale (P/S) ratio is 64.78 while its Price-to-Book (P/B) ratio in mrq is 20.61. Its current Enterprise Value per Revenue stands at 61.969 whereas that against EBITDA is -26.889.
Stock Price History:
The Beta on a monthly basis for INSM is 0.95, which has changed by 0.6294911 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, INSM has reached a high of $114.03, while it has fallen to a 52-week low of $60.40. The 50-Day Moving Average of the stock is 22.77%, while the 200-Day Moving Average is calculated to be 53.49%.
Shares Statistics:
The stock has traded on average 3.68M shares per day over the past 3-months and 3581890 shares per day over the last 10 days, according to various share statistics. A total of 211.11M shares are outstanding, with a floating share count of 206.91M. Insiders hold about 2.11% of the company’s shares, while institutions hold 96.74% stake in the company. Shares short for INSM as of 1753920000 were 9537045 with a Short Ratio of 2.59, compared to 1751241600 on 9796337. Therefore, it implies a Short% of Shares Outstanding of 9537045 and a Short% of Float of 5.0.
Earnings Estimates
The current assessment of Insmed Inc (INSM) involves the perspectives of 13.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$1.21, with high estimates of -$0.58 and low estimates of -$1.96.
Analysts are recommending an EPS of between -$4.87 and -$6.11 for the fiscal current year, implying an average EPS of -$5.53. EPS for the following year is -$4.05, with 13.0 analysts recommending between -$2.58 and -$9.55.
Revenue Estimates
15 analysts predict $115.26M in revenue for the current quarter. It ranges from a high estimate of $123.5M to a low estimate of $108.9M. As of the current estimate, Insmed Inc’s year-ago sales were $93.42MFor the next quarter, 15 analysts are estimating revenue of $152.61M. There is a high estimate of $175.94M for the next quarter, whereas the lowest estimate is $130.1M.
A total of 18 analysts have provided revenue estimates for INSM’s current fiscal year. The highest revenue estimate was $498.14M, while the lowest revenue estimate was $439.3M, resulting in an average revenue estimate of $468.91M. In the same quarter a year ago, actual revenue was $363.71MBased on 17 analysts’ estimates, the company’s revenue will be $1.02B in the next fiscal year. The high estimate is $1.23B and the low estimate is $865M.
